---
id: antimicrobials_novel-tetracyclines_035
category: antimicrobials
tags: [antimicrobials, omadacycline, eravacycline, tetracyclines, novel-antibiotics]
deck: Infectious Diseases
created: 2025-11-10
modified: 2025-11-10
---

## Novel Tetracyclines: Omadacycline & Eravacycline

**Q:** How do omadacycline and eravacycline differ from tigecycline, and what are their indications?

**A:**

**Third-Generation Tetracyclines:**
- Tigecycline (2005), Eravacycline (2018), Omadacycline (2018)

**Mechanism Advantage:**
- **Evade efflux and ribosomal methylation resistance**
- Overcome resistance mechanisms that affect older tetracyclines (including tigecycline)

---

## **Omadacycline**

**Classification:** Aminomethylcycline (semi-synthetic from minocycline)

**Route:** **Oral AND IV** (unique advantage over tigecycline)

**FDA-Approved Indications:**
1. **Community-acquired bacterial pneumonia (CABP)**
2. **Acute bacterial skin and skin structure infections (ABSSSI)**
3. **Orphan indication:** First-line for nontuberculous mycobacteria (NTM), especially M. abscessus (US)

**Spectrum:**
- Broad-spectrum: Aerobic/anaerobic Gram-positive and Gram-negative
- **MRSA**, VRE, doxycycline-resistant Strep pneumoniae
- **Atypicals:** Mycoplasma, Chlamydia, Legionella
- Several enteric Gram-negatives

**Does NOT cover:**
- ❌ Proteus, Providencia, **Pseudomonas**, Morganella, Eikenella (MIC90 ≥16 µg/mL)

**Dosing:**
- **Loading:** 200 mg x1, then 100 mg daily (IV or PO)

---

## **Eravacycline**

**Route:** **IV only**

**FDA-Approved Indication:**
- **Complicated intra-abdominal infections (cIAI)**

**Spectrum:**
- Similar broad-spectrum to omadacycline
- Excellent activity against Gram-positive, Gram-negative, atypicals, anaerobes

---

## **Comparison: Tigecycline vs Omadacycline vs Eravacycline**

| **Feature** | **Tigecycline** | **Omadacycline** | **Eravacycline** |
|-------------|-----------------|------------------|------------------|
| **Route** | IV only | **IV + PO** | IV only |
| **FDA Indications** | cIAI, cSSSI | **CABP, ABSSSI, NTM** | cIAI |
| **Pseudomonas** | ❌ No | ❌ No | ❌ No |
| **Resistance evasion** | Limited | ✅ Better | ✅ Better |
| **CAP use** | ❌ Not indicated | ✅ Yes | ❌ No |

**Mnemonic: "Omada-CYCLE = Oral AND Cycline for CAP"**
- **Omada** = Oral availability (IV or PO)
- **CYCLE** = Cycline (tetracycline)
- **CAP** = FDA-approved for CAP

**Clinical Pearl:**
- **Omadacycline advantage:** Oral bioavailability (IV-to-PO switch, outpatient therapy)
- Think of omadacycline for **MRSA CABP** or **ABSSSI** with PO step-down need
- None cover Pseudomonas (like tigecycline limitation)

**Media:** None

**Sources:** [PMC 2024 - Third-gen tetracyclines], [AAC 2024 - Omadacycline perspectives], [Annals of Medicine 2022], [PMC 2019 - Omadacycline review], [PharmacoEcon Outcomes Res 2023 - Novel tetracyclines review]
